Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MP101 in Acute Pseudomonas Aeruginosa Pneumonia
NCT07492771Phase 1Recruiting
- Start
- Jul 2026
- Primary completion
- Dec 2026
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Lactobacillus salivarius in Pseudomonas aeruginosa pneumonia (3 arms). Primary endpoint: Adverse Events. Started Jul 2026; status: recruiting.
02
Drugs
Lactobacillus salivarius
03
Conditions
Pseudomonas aeruginosa pneumonia
Beyond the preview
Go deeper on NCT07492771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07492771.